Three‐year experience with access to nationally funded growth hormone (<scp>GH</scp>) replacement for <scp>GH</scp>‐deficient adults

Abstract

Carefully designed access to nationally funded GH replacement in GH-deficient adults was associated with a significant improvement in quality of life over a 3-year period with mean daily GH doses lower than in the majority of previously reported studies.